EUVIMEDEUVIMED entdecken
Validierungsstudie

Clinical Validation of the Venus HPV Full‐Genotyping Assay for Cervical Cancer Screening in the VALGENT‐4 Framework

Lan Xu iD, Chang Ma, Kate Cuschieri, Jesper Bonde, Marc Arbyn iD

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70527 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Lan Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Early Detection of Cancer, Papillomavirus Infections, Papillomaviridae. Die Arbeit nennt 28 Literaturangaben. Gefördert von: L.X. was supported by the Fundamental Research Funds for the Central Universities (Grant No. YG2023QNB03, China); M.A. was supported by the RISCC Network (Gran….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Venus HPV assay (VenusHPV) is a real‐time PCR‐based human papillomavirus (HPV) test that is widely used in China but lacks extensive clinical validation. The VALidation of HPV GENotyping Tests (VALGENT) framework is an established protocol for evaluating HPV genotyping assays against a standard comparator test. This study aimed to assess the clinical accuracy and reproducibility of the VenusHPV assay following international validation criteria. The clinical performance of VenusHPV was evaluated against the GP5+/6+ PCR‐based enzyme immunoassay (GP‐EIA) using the VALGENT‐4 panel, which included 998 consecutive routine screening samples enriched with 297 samples with abnormal cytology from the Danish cervical cancer screening program. Cases were defined as women diagnosed with histologically confirmed cervical intraepithelial neoplasia 2 or more (CIN2+), while two consecutive negative cytology results served as a proxy for nondisease. Intra‐ and interlaboratory reproducibility was assessed on 500 samples. Using the manufacturer‐recommended cutoff, VenusHPV demonstrated noninferior sensitivity for detection of CIN2+, but its specificity for ≤ CIN1 was inferior to that of GP‐EIA. Applying an optimized a posteriori cutoff improved the specificity, yielding relative specificity of 1.02 (95% CI [CI], 1.00–1.03; p noninferiority [ p n.inf ] < 0.0001), while maintaining a noninferior sensitivity (of 1.02; CI, 1.00–1.08; p n.inf < 0.0001). The intra‐ and interlaboratory reproducibility was excellent (95.2%, CI, 93.3–97.1%, Kappa [ κ ] = 0.87 and 94.0%, CI, 92.0%–96.0%, κ = 0.85, respectively). Notably, the reproducibility criteria were met consistently, regardless of whether the unadjusted or optimized cutoff was applied. The VenusHPV was as sensitive as the GP‐EIA for detecting cervical precancer using the unadjusted cutoff but less specific. However, after cutoff optimization, VenusHPV met the international accuracy criteria for cervical cancer screening. Additionally, the assay demonstrated excellent reproducibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsEarly Detection of CancerPapillomavirus InfectionsPapillomaviridaeGenotyping TechniquesUterine Cervical DysplasiaHumansFemaleReproducibility of ResultsSensitivity and SpecificityAdultMiddle AgedGenotypeReal-Time Polymerase Chain ReactionDenmarkAged

Stichwörter der Autor:innen

GP‐EIAVALGENTVenusHPVcervical cancer screeningclinical validation studydiagnostic test accuracyhuman papillomavirusreproducibility

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK.
  • Molecular Pathology Laboratory, Department of Pathology, afs.134, AHH-Hvidovre Hospital, Hvidovre, Denmark.
  • Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.

ORCID-Profile: Lan Xu, Marc Arbyn

Förderung

  • L.X. was supported by the Fundamental Research Funds for the Central Universities (Grant No. YG2023QNB03, China); M.A. was supported by the RISCC Network (Gran…

Zitieren

APA

Xu, L., Ma, C., Cuschieri, K., Bonde, J., & Arbyn, M. (2025). Clinical Validation of the Venus HPV Full‐Genotyping Assay for Cervical Cancer Screening in the VALGENT‐4 Framework. Journal of Medical Virology. https://doi.org/10.1002/jmv.70527

Vancouver

Xu L, Ma C, Cuschieri K, Bonde J, Arbyn M. Clinical Validation of the Venus HPV Full‐Genotyping Assay for Cervical Cancer Screening in the VALGENT‐4 Framework. Journal of Medical Virology. 2025. doi:10.1002/jmv.70527

BibTeX
@article{Xu2025,
  author = {Xu, Lan and Ma, Chang and Cuschieri, Kate and Bonde, Jesper and Arbyn, Marc},
  title = {Clinical Validation of the Venus HPV Full‐Genotyping Assay for Cervical Cancer Screening in the VALGENT‐4 Framework},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70527}
}
Kostenlos starten →